Aclaris Therapeutics, Inc. (FRA:8AT)

Market Cap	424.68M +174.0%
Revenue (ttm)	6.67M -58.2%
Net Income	-55.29M
EPS	-0.45
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	91
Open	3.016
Previous Close	3.040
Day's Range	3.016 - 3.016
52-Week Range	0.956 - 3.809
Beta	n/a
RSI	52.34
Earnings Date	May 7, 2026

About Aclaris Therapeutics

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 71
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8AT

Financial Performance

In 2025, Aclaris Therapeutics's revenue was $7.83 million, a decrease of -58.19% compared to the previous year's $18.72 million. Losses were -$64.92 million, -50.84% less than in 2024.

Financial numbers in USD